infliximab-abda

Drug Overview

In the field of Gastroenterology, managing chronic, immune-mediated diseases requires advanced and effective medical interventions. Infliximab-abda is a powerful BIOLOGIC medication and a highly specialized TARGETED THERAPY. It belongs to a class of drugs known as TNF-Alpha Inhibitors. As a biosimilar to the original infliximab, it is designed to treat severe inflammation in the digestive tract, offering patients a chance to achieve long-term remission and improve their daily quality of life. This MONOCLONAL ANTIBODY represents a major advancement in treating complex digestive disorders when traditional medications have failed.

• Generic Name / Active Ingredient: Infliximab-abda
• US Brand Names: Renflexis
• Drug Category: Gastroenterology
• Drug Class: TNF-Alpha Inhibitor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: FDA-Approved as a biosimilar to Remicade (infliximab)

What Is It and How Does It Work? (Mechanism of Action)

Infliximab-abda is a chimeric MONOCLONAL ANTIBODY, meaning it is a lab-created protein designed to act like human antibodies in the immune system. To understand how this BIOLOGIC works, we must look closely at a specific protein in the body called Tumor Necrosis Factor-alpha (TNF-alpha).

In patients with certain gastrointestinal diseases, the immune system becomes overactive and produces too much TNF-alpha. This excess protein acts as a messenger, signaling the body to create severe, continuous inflammation in the lining of the intestines. This constant inflammation damages the intestinal walls, leading to ulcers, bleeding, and severe digestive symptoms.

Infliximab-abda works by specifically targeting and binding to these excess TNF-alpha proteins in the bloodstream and on cell surfaces. By locking onto TNF-alpha, the drug physically blocks the protein from attaching to its receptors on the cells of the gut. Furthermore, it causes the direct breakdown (apoptosis) of the immune cells that are producing the inflammation. By stopping this inflammatory cascade at the molecular level, this TARGETED THERAPY allows the damaged intestinal tissue to finally heal, a process known as mucosal healing.

FDA-Approved Clinical Indications

Primary Indication

Renflexis (infliximab-abda) is primarily utilized as a biosimilar BIOLOGIC therapy to reduce signs and symptoms, achieve clinical remission, and promote intestinal healing in patients with moderate to severe inflammatory bowel diseases.

Primary Gastroenterology Indications

• Crohn’s Disease (Adult and Pediatric): Used for patients who have had an inadequate response to conventional therapies. It reduces inflammation across the entire digestive tract, helps close painful fistulas (abnormal connections between the bowel and other organs), and restores normal nutrient absorption.
• Ulcerative Colitis (Adult and Pediatric): Used for patients experiencing moderate to severe flare-ups. It helps to stop the immune attack on the colon lining, significantly reducing symptoms like bloody diarrhea and abdominal cramping, and promoting the healing of colon ulcers.

Other Approved & Off-Label Uses

While highly effective in Gastroenterology, this TARGETED THERAPY is also FDA-approved to treat other autoimmune conditions driven by TNF-alpha:

• Rheumatoid Arthritis (in combination with methotrexate)
• Ankylosing Spondylitis
• Psoriatic Arthritis
• Plaque Psoriasis
• Off-Label GI Uses: Occasionally used in severe, refractory microscopic colitis or immune-mediated enteropathy, though these are strictly at the physician’s discretion.

Dosage and Administration Protocols

Infliximab-abda is administered entirely via intravenous (IV) infusion in a clinical setting. The infusion typically takes about two hours to complete.

Indication	Standard Dose	Frequency
Crohn’s Disease (Adult & Pediatric)	5 mg/kg IV infusion	Weeks 0, 2, and 6, then every 8 weeks
Fistulizing Crohn’s Disease	5 mg/kg IV infusion	Weeks 0, 2, and 6, then every 8 weeks
Ulcerative Colitis (Adult & Pediatric)	5 mg/kg IV infusion	Weeks 0, 2, and 6, then every 8 weeks

Dose Adjustments and Considerations:

• Renal or Hepatic Insufficiency: There are no formal dose adjustments required for patients with kidney or liver impairment, but physicians will monitor these patients closely for potential complications.
• Loss of Response: If a patient stops responding to the standard dose, a physician may increase the dose up to 10 mg/kg or shorten the interval between infusions to every 4 to 6 weeks.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

As a biosimilar, Renflexis has undergone rigorous testing to prove it has no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Current clinical data from 2020 to 2026 continues to support the high efficacy of infliximab products in achieving deep remission.

In major clinical trials evaluating patients with moderate to severe Crohn’s Disease and Ulcerative Colitis, infliximab therapies have demonstrated remarkable results. Research shows that approximately 60 to 70 percent of patients experience a significant clinical response (a major reduction in symptoms) within the first 8 weeks of starting therapy. Furthermore, up to 30 to 40 percent of patients achieve complete clinical remission by week 30.

Beyond just symptom relief, this BIOLOGIC is highly effective at achieving mucosal healing. Endoscopy scores from clinical studies reveal that over 50 percent of patients on maintenance therapy show visible healing of the intestinal lining, which drastically reduces the need for future bowel surgeries and lowers the risk of colon cancer associated with chronic inflammation.

Safety Profile and Side Effects

BLACK BOX WARNING: Serious Infections: Patients treated with infliximab-abda are at an increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), invasive fungal infections, and other opportunistic infections.

Malignancies: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. A rare and usually fatal type of lymphoma called Hepatosplenic T-cell Lymphoma (HSTCL) has occurred, mostly in young adult males with inflammatory bowel disease.

Common Side Effects (Occurring in >10% of patients)

• Respiratory infections (such as sinus infections or sore throat)
• Infusion-related reactions (mild rash, itching, chills, or flushing during treatment)
• Headaches
• Abdominal pain and nausea
• Fatigue

Serious Adverse Events

• Hepatotoxicity: Rare cases of severe liver injury.
• Demyelinating Disease: Rare nervous system disorders like multiple sclerosis or Guillain-Barre syndrome.
• Heart Failure: Can worsen or cause new-onset congestive heart failure.
• Lupus-like Syndrome: A rare immune reaction causing joint pain and rash, which usually resolves after stopping the drug.

Management Strategies

Healthcare teams closely monitor patients during and after the two-hour IV infusion to manage any immediate reactions. Acetaminophen or antihistamines may be given before the infusion to prevent mild allergic responses. Patients must report any signs of infection, such as a persistent fever or cough, immediately to their doctor.

Connection to Mucosal Immunology and Microbiome Research

Recent research into Mucosal Immunology highlights how this MONOCLONAL ANTIBODY physically changes the environment of the gut. By neutralizing TNF-alpha, infliximab-abda helps repair the intestinal epithelial barrier, effectively “sealing” the gut lining and preventing harmful bacteria from leaking into the bloodstream (a condition sometimes called leaky gut).

Furthermore, ongoing microbiome research from 2020 onward shows that achieving remission with this BIOLOGIC leads to positive shifts in the gut’s bacterial makeup. Chronic inflammation limits bacterial diversity, but as the gut heals, patients often experience a rebound in beneficial bacteria, particularly species from the Firmicutes group, which produce short-chain fatty acids that further protect the colon lining. This indicates that stopping inflammation not only heals the tissue but also helps restore a healthy, balanced microbiome.

Disclaimer: Research regarding the direct induction of microbial repopulation (specifically short-chain fatty acid-producing bacteria) as a primary consequence of infliximab-induced barrier restoration is currently in the investigative phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before initiating therapy with this SMALL MOLECULE-blocking biologic, physicians must conduct a thorough safety and baseline assessment:

• Baseline Diagnostics: A recent endoscopy or colonoscopy is necessary to document the severity of the disease. Fecal calprotectin tests are also used to measure baseline gut inflammation.
• Specialized Testing: Because of the Black Box Warning, all patients must be screened for latent Tuberculosis (TB) and Hepatitis B. If a patient carries these infections, they must be treated before starting the BIOLOGIC.
• Organ Function: Liver function tests (LFTs) and a complete blood count (CBC) are required to ensure the liver and immune system are stable enough for therapy.
• Screening: Blood tests to check for nutritional deficiencies common in GI disorders, such as Vitamin B12, Iron, and Vitamin D, along with inflammatory markers like CRP and ESR.

Monitoring and Precautions

• Vigilance (Therapeutic Drug Monitoring): Over time, some patients’ immune systems may recognize the drug as an invader and create “anti-drug antibodies.” This can cause the medication to stop working. Doctors regularly check blood levels of the drug and these antibodies to adjust the dose and prevent this “loss of response.”
• Lifestyle: Patients are encouraged to maintain proper hydration and adopt dietary modifications tailored to their specific triggers (such as a low-residue diet during flare-ups). Smoking cessation is absolutely critical, especially for Crohn’s Disease patients, as smoking directly counteracts the drug’s healing effects.

Do’s and Don’ts

• DO keep all appointments for your scheduled IV infusions; skipping doses increases the risk of your body rejecting the drug.
• DO get your annual flu shot and other non-live vaccines as recommended by your doctor.
• DON’T receive any “live” vaccines (like yellow fever or the live shingles vaccine) while on this medication, as your immune system cannot process them safely.
• DON’T ignore minor signs of infection, such as a mild fever, persistent cough, or a small skin sore, as they can escalate quickly while on an immunosuppressant.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, gastroenterologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, new medication, or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in this material.